Kurin Inc., the inventor and manufacturer of the Kurin^® blood culture collection sets, announced that July revenues represent their highest monthly total in their history. Kurin also reports that July exceeded 200% over the same month in 2019, before the pandemic began.

“We are living in unprecedented times with hospitals struggling in an unfamiliar world, so it is particulary rewarding to see the continued growth of our business,” said Bob Rogers, CEO of Kurin, Inc. “Demand for Kurin products is at an all-time high as we help hospitals manage their way through an uneven and unpredictable pandemic. We represent a source of clinical and financial improvement for hospitals, and the performance we have seen demonstrates that many hospitals see Kurin as a rare opportunity to improve on both levels.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. The Kurin device passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. Kurin, manufactured in San Diego, CA, has received FDA 510(k) market clearance. For more information about Kurin, visit the website at www.kurin.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005056/en/